Jade Biosciences, Inc. (JBIO)
Automate Your Wheel Strategy on JBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including JBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JBIO
- Rev/Share 0.0
- Book/Share -9.3594
- PB -0.89
- Debt/Equity -2.2993
- CurrentRatio 5.8064
- ROIC -1.169
- MktCap 268525047.0
- FreeCF/Share -9.0456
- PFCF -5937.1417
- PE -0.4433
- Debt/Assets 1.478
- DivYield 0.2881
- ROE 2.0078
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | JBIO | Jefferies | -- | Buy | -- | $16 | July 14, 2025 |
| Upgrade | JBIO | Guggenheim | Neutral | Buy | -- | $14 | June 16, 2025 |
| Initiation | JBIO | Wedbush | -- | Outperform | -- | $17 | May 7, 2025 |
| Initiation | JBIO | Stifel | -- | Buy | -- | $19 | May 5, 2025 |
| Initiation | JBIO | TD Cowen | -- | Buy | -- | $10 | May 2, 2025 |
News
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled “Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN,” will be delivered during the Focused Oral …
Read More
About Jade Biosciences, Inc. (JBIO)
- IPO Date 2025-04-29
- Website https://jadebiosciences.com
- Industry Biotechnology
- CEO Tom Frohlich
- Employees 50